JPRN-UMIN000005843
Recruiting
未知
A Multi-center Phase II Study evaluating efficacy and safety of Dasatinib in Patients with newly diagnosed Philadelphia(Ph) chromosome positive Chronic Myeloid Leukemia in chronic phase. - A Multi-center Phase II Study evaluating efficacy and safety of Dasatinib.
Epidemiological and Clinical Research Information Network (ECRIN)0 sites30 target enrollmentJune 24, 2011
ConditionsChronic Myeloid Leukemia
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Chronic Myeloid Leukemia
- Sponsor
- Epidemiological and Clinical Research Information Network (ECRIN)
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Previous treatment with TKI or IFN\-alpha
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study assessing if a chemotherapy drug called Cabazitaxel is effective in Patients with certain type of breast cancer (HER2 negative) that has spread to brain that is un treatable.Her-2 negative breast cancer with brain metastasesMedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-000542-35-GBThe Clatterbridge Cancer Centre NHS Foundation Trust19
Completed
Phase 2
Efficacy of cabazitaxel in patients with HER2-negative metastatic breast cancerPatients with HER2-negative metastatic breast cancer and having unresectable brain metastases.CancerMalignant neoplasm of breastISRCTN79877830The Clatterbridge Cancer Centre NHS Foundation Trust (UK)19
Recruiting
Phase 1
Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF (V600E) mutated MSS, initially resectable or potentially resectable advanced colorectal cancer: CEBBRA study.BRAF V600E mutated and microsatellite stable (MSS) advanced colorectal cancer (aCRC) initially resectable or potentially resectableMedDRA version: 21.0Level: PTClassification code: 10052360Term: Colorectal adenocarcinoma Class: 100000004864Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2022-502413-29-00Asociacion Grupo Tratamiento De Tumores Digestivos70
Active, not recruiting
Phase 1
A multicenter phase II study evaluating the effect and tolerability of vemurafenib in combination with Pegylated Interferon and Interleukin-2 in patients with metastatic melanoma positive for the BRAF-mutatioEUCTR2013-000773-71-DKDepartment of Oncology, Aarhus University Hospital50
Active, not recruiting
Not Applicable
Study to assess the efficacy and the safetyof front-line therapy (Fludarabine, Cyclophosphamide and Ofatumumab) in young (=65 yrs) patientswith Chronic Lymphocytic Leukemia (CLL)EUCTR2011-005329-27-ITG.I.M.EM.A.Gruppo Italiano Malattie Ematologiche dell'Adulto